Thiamethoxam belongs to the second-generation neonicotinoid insecticides, mainly acting on nicotinic acetylcholine receptors (nAChR) . Severe poisoning cases can lead to respiratory failure, shock, and even death. There are relatively few reports on thiamethoxam poisoning, and few literature reports on concurrent rhabdomyolysis cases have been found so far. This article reviews the treatment process of a case of oral thiamethoxam poisoning. The patient developed mild rhabdomyolysis (CK: 1581 U/l) and renal dysfunction (creatinine: 127 μmol/L) immediately after taking the medication, reaching its peak on the second day (CK: 16329 U/l) . After active treatment (such as Blood purification, drainage, gastrointestinal decompression and organ support) , the symptoms of rhabdosis gradually improved and the patient was discharged. It is suggested that when treating thiamethoxam poisoning, the occurrence of rhabdomyolysis syndrome should be concerned.

Thiamethoxam belongs to the second-generation neonicotinoid insecticides, mainly acting on nicotinic acetylcholine receptors (nAChR) . Severe poisoning cases can lead to respiratory failure, shock, and even death. There are relatively few reports on thiamethoxam poisoning, and few literature reports on concurrent rhabdomyolysis cases have been found so far. This article reviews the treatment process of a case of oral thiamethoxam poisoning. The patient developed mild rhabdomyolysis (CK: 1581 U/l) and renal dysfunction (creatinine: 127 μmol/L) immediately after taking the medication, reaching its peak on the second day (CK: 16329 U/l) . After active treatment (such as Blood purification, drainage, gastrointestinal decompression and organ support) , the symptoms of rhabdosis gradually improved and the patient was discharged. It is suggested that when treating thiamethoxam poisoning, the occurrence of rhabdomyolysis syndrome should be concerned.

Objective To investigate the cytotoxic effects of IL-2 combined with different dosages of sorafenib on renal cellular carcinoma cell line 786-0. Methods Renal carcinoma cell 786-0 was cultured. Then , IL-2 (20 μmol/L) combined with different dosages of sorafenib (6.9, 13.8, 20.8 μmol/L) were used to treat tumor cell 786-0. The inhibitory effect on cell proliferation was determined by MTT assay. Cell apoptosis was measured by Annexin V-FITC kit. The tumor-bearing mice models were established and divided into four groups. Results The tumor cell growth was inhibited with the time-course correlation in all groups. In the 48-hour high doses group, the inhibitory rate was up to (74.67±1.87) %. The rates of cell proliferation inhibition and cell apoptosis were higher in the high dosages group than those in the other groups. Conclusions Immunotherapy combined with target therapy could significantly inhibit the growth of renal cellular carcinoma. But we should find a proper dosage, which could improve the clinical effect and reduce the adverse effect.